Vaccine Stocks Ranked: mRNA Won Flu, PCVX Next Binary

The market wrote off vaccines after COVID, and that is the setup. Moderna fell from $496 to $54. Novavax handed its COVID shot to Sanofi. Analysts stopped modeling flu and RSV as anything but declining annuities. Then August happened. Moderna’s mRNA flu vaccine got approved on August 5, and its cancer vaccine cleared Phase 3 on August 19, re-rating the stock 177% in a day. Vaccines are not dead. They are mid-repricing, and the platform war underneath is just getting interesting.

Here is the frame that matters. Vaccines split into three economic regimes. The mRNA platform, led by Moderna and BioNTech, wins on speed: strain-matched shots designed in weeks, and it just produced the first positive Phase 3 cancer vaccine. The protein and adjuvanted platform, led by GSK, Pfizer, Sanofi, and Novavax, wins on durability and tolerability but is losing the innovation race. And the next-generation shelf, combination shots and higher-valency pneumococcal vaccines, is where the next binary catalysts sit. Prices below are from the August 31, 2026 close. A prior piece covered the mRNA platform economics and the full platform comparison separately.

1. Vaxcyte (PCVX): the Q4 binary that threatens Merck’s franchise

Vaxcyte closed at $60.74 with an $8.90 billion market cap and zero product revenue. It is the purest binary on this list, and it is the one to watch closest.

VAX-31 is a 31-valent pneumococcal conjugate vaccine, the broadest-spectrum PCV in the clinic. It is designed to cover roughly 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia in US adults 50 and older, versus about 61% to 69% for the incumbent PCV20. In the Phase 1/2 study, VAX-31 met superiority criteria on all 11 incremental serotypes versus PCV20 and delivered higher opsonophagocytic responses on 18 of the 20 shared serotypes. The Phase 1/2 results were published in The Lancet Infectious Diseases in March 2026.

The catalyst is the OPUS-1 registrational Phase 3 noninferiority trial (NCT07284654), a roughly 4,000-patient head-to-head against both Prevnar 20 and Merck’s Capvaxive PCV21. Topline data is expected in the fourth quarter of 2026, with OPUS-2 and OPUS-3 following in the first half of 2027 and a BLA submission planned after. This is the trade: a pre-revenue $8.90 billion company whose lead asset, if the data hits, resets the standard of care for the roughly $10 billion pneumococcal market that Merck currently dominates. If OPUS-1 shows noninferiority plus superiority on the incremental serotypes, the stock re-rates toward the value of the PCV franchise it would disrupt. If the immunogenicity comes in soft, a pre-revenue company at $8.90 billion has a long way to fall. This is a 1% to 2% binary option, not a core holding. Read the how vaccines get FDA approved guide for the regulatory path.

2. Moderna (MRNA): the re-rated leader, now an execution story

Moderna closed at $140.34 with a $55.1 billion market cap, up from $54 before the August catalysts. The easy money is made. What remains is execution.

Two things happened. First, the FDA approved mFLUVISA on August 5, the first mRNA seasonal flu vaccine in the US, on 26.6% higher relative efficacy than standard-dose flu shots. A prior piece covered the flu PDUFA and approval. Second, and far more consequential, the Phase 3 INTerpath-001 trial of intismeran, the individualized cancer vaccine partnered with Merck, met its primary endpoint of recurrence-free survival in adjuvant melanoma at a pre-planned interim analysis on August 19. The stock surged 177% that day. A prior piece covered the cancer vaccine platform in depth, so the data is not repeated here. The point for this ranking: the market now prices Moderna as a cancer vaccine company with a flu and RSV bridge, not a declining COVID annuity.

The near-term risk is that norovirus stalled, flu is one season away from proving commercial traction, and the intismeran hazard ratio and regulatory filing are still pending. At $55.1 billion, Moderna has moved from undervalued to fairly valued on the bull case. Do not chase here. Hold, and revisit on the intismeran filing and the ACIP flu recommendation.

3. BioNTech (BNTX): the cash-rich oncology pivot

BioNTech closed at $101.61 with a $25.6 billion market cap and roughly EUR 17 billion in cash. The company is pivoting hard toward oncology, where its individualized neoantigen vaccine autogene cevumeran (BNT122) and its bispecific and cell therapy programs sit. It is the closest competitor to Moderna in cancer vaccines but is further behind: its lead data is Phase 1 in pancreatic cancer, not Phase 3 in melanoma.

The infectious disease franchise is the quieter asset. BioNTech has combination flu-COVID and next-generation vaccine programs, and its cash position means it can fund the oncology pivot without the dilution risk that kills most biotechs. At $25.6 billion against a $55.1 billion Moderna, BioNTech trades at a discount because its cancer vaccine is earlier and its infectious disease revenue is smaller. That discount is the argument. It ranks third: hold, with the caveat that the catalyst that moves BioNTech is a Phase 3 cancer vaccine readout, which is further out than Moderna’s.

4. Merck (MRK): the franchise Vaxcyte is trying to disrupt

Merck closed at $147.76 with a $366.0 billion market cap. It owns the pneumococcal franchise Vaxcyte is aiming at. Capvaxive, the PCV21 designed specifically for adults, launched in late 2024 and pulled in $530 million over its first four quarters, including $244 million in Q3 2025, and Merck expanded its indication on August 13, 2026. Meanwhile Gardasil sales slumped 39% in 2025 on weak China demand.

Merck is the partner on Moderna’s intismeran, so it wins either way on cancer vaccines. But at $366 billion, neither Capvaxive nor intismeran moves the stock. A Vaxcyte OPUS-1 success would be a genuine competitive threat to a franchise that is one of Merck’s vaccine growth engines, but even a lost pneumococcal share fight is immaterial to the market cap. Merck is a Hold here, and the more useful signal from Merck is what it tells you about Vaxcyte: if a $366 billion company is spending to defend its PCV franchise, the market Vaxcyte is attacking is real and large.

5. GSK (GSK): the protein incumbent that is holding its ground

GSK closed at $50.25 with a $101.8 billion market cap. It is the RSV vaccine leader, with Arexvy, which the FDA expanded to adults 18 to 49 at increased risk in March 2026. The RSV market is a three-player race among Arexvy, Pfizer’s Abrysvo, and Moderna’s mResvia, and a prior piece covered the RSV battle separately. The drag is Shingrix, where US demand fell 15% and pulled overall vaccine growth down to 2%.

GSK is the recurring-revenue vaccine franchise: durable, but not a binary catalyst. Arexvy and Shingrix generate dependable cash flow, and the company is not betting the balance sheet on any single readout. For a vaccine investor who wants lower binary risk, GSK is the hold-and-collect name. It will not double, and it will not halve.

6. Pfizer (PFE) and Novavax (NVAX): the protein laggards

Pfizer closed at $28.46 with a $159.4 billion market cap. Its vaccine franchise is Abrysvo in RSV and Comirnaty in COVID, both mature and declining, and its broader story is the obesity pivot, not vaccines. There is no near-term vaccine catalyst here that moves a $159 billion company.

Novavax closed at $9.37 with a $1.53 billion market cap. It licensed its COVID shot and Matrix-M adjuvant to Sanofi under a co-exclusive deal and is now a protein-based player dependent on a partner for its only real revenue. The company transferred the US marketing authorization for Nuvaxovid to Sanofi, triggering a $25 million milestone, but a $1.53 billion market cap with a partner-dependent revenue stream and no differentiated pipeline is an Avoid, not a Hold.

Risks

The specific risk across this shelf is policy and seasonality, not science. ACIP recommendation timing determines whether Moderna’s mFLUVISA gets a real commercial launch or a technical approval, and the advisory committee’s stance on vaccine uptake under a skeptical administration is a live variable. Pneumococcal and RSV demand is cyclical and contract-driven. For Vaxcyte specifically, the risk is the binary itself: a Phase 3 immunogenicity miss against Merck’s entrenched PCV would cut a pre-revenue $8.90 billion company hard. For Moderna, the risk is that the intismeran hazard ratio, when disclosed, is weaker than the 0.51 seen in Phase 2b, shrinking the peak sales the market just priced in.

The verdict

Ranked by risk-adjusted investment relevance:

1. Vaxcyte (PCVX): The pure binary. Q4 OPUS-1 topline against the $10 billion pneumococcal franchise. A 1% to 2% option on a standard-of-care reset.
2. Moderna (MRNA): The re-rated winner. The 177% move is done; now it is execution on intismeran’s filing and the flu launch. Hold, do not chase.
3. BioNTech (BNTX): The discounted mRNA pure play with a cash cushion. Hold for the later cancer vaccine readout.
4. Merck (MRK): PCV franchise and intismeran partner, immaterial to a $366 billion cap. Hold.
5. GSK (GSK): The recurring-revenue vaccine franchise. Hold and collect.
6. Pfizer (PFE): Mature, declining, no near-term vaccine catalyst. Avoid for vaccine exposure.
7. Novavax (NVAX): Partner-dependent protein player with no differentiated pipeline. Avoid.

The contrarian takeaway: the market wrote off vaccines as a post-COVID afterthought, and in the space of three weeks mRNA delivered a flu approval and a positive Phase 3 cancer vaccine. The platform war is not over, but the next trade is not the mRNA versus protein fight. It is Vaxcyte’s 31-valent pneumococcal shot against Merck’s franchise in the fourth quarter. That is the binary worth positioning for, and it is the one name on this list where a single data readout still changes the valuation by tens of billions.